SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that...
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confi...
SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactur...
PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owne...
SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Mor...
* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of th...
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Compan...
SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactur...
PHILADELPHIA and MUNICH, Dec. 1, 2020 /PRNewswire/ -- ViGeneron, a gene therapy company, and WuXi A...